|Dr. Eliot Richard Forster M.B.A., Ph.D.||Pres, CEO & Director||1.05M||N/A||1966|
|Ms. Darlene M. Deptula-Hicks||CFO & Treasurer||672.38k||N/A||1957|
|Dr. Neil Brewis||Chief Scientific Officer||594.4k||N/A||N/A|
|Dr. Louis Kayitalire||Chief Medical Officer||716.89k||N/A||N/A|
|Lindsey Trickett||VP of Investor Relations & Communications||N/A||N/A||N/A|
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118, is currently being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.
F-star Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.